Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANALYSIS: Unravelling Japan’s Biosimilar Opportunities

This article was originally published in PharmAsia News

Executive Summary

MP Advisors sees a cumulative biosimilars opportunity of around JPY400 billion ($3.31 billion) in Japan over the next five years as some big-selling biologics come off local patent. But the next few years will provide further clarity on the value of different strategies for complex monoclonal antibody (mAb) biosimilar penetration in the country.

You may also be interested in...



Japan Rebound For Amgen With Daiichi Biosimilars Deal

A few weeks after its R&D alliance in Japan with Takeda was scaled back, Amgen has found a new partner in the country, this time for the commercialization of a broad portfolio of biosimilars.

Japan Rebound For Amgen With Daiichi Biosimilars Deal

A few weeks after its R&D alliance in Japan with Takeda was scaled back, Amgen has found a new partner in the country, this time for the commercialization of a broad portfolio of biosimilars.

Quick Listen: Scrip’s Five Must-Know Things

Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things. 

Topics

Related Companies

UsernamePublicRestriction

Register

OM004559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel